Compass Therapeutics
CMPX
55 hedge funds and large institutions have $401M invested in Compass Therapeutics in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 4 reducing their positions, and 1 closing their positions.
1,800% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 1
475% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 4
176% more capital invested
Capital invested by funds: $146M → $401M (+$256M)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
45% more funds holding
Funds holding: 38 → 55 (+17)
0.02% more ownership
Funds ownership: 63.25% → 63.26% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$12.4M |
| 2 |
Janus Henderson Group
London,
|
+$9.64M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$6.21M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$6.21M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$659K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$93.8K |
| 3 |
Renaissance Technologies
New York
|
-$49.1K |
| 4 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
-$9.97K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
CMPX Hedge Fund Activity: Q4 2022 in Review
55 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q4 2022, worth a combined $401M — up 176% from $146M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CMPX positions and 1 closed out — a net gain of 18 holders — while 23 added to existing stakes and 4 trimmed.
The largest buyer was Blackstone Inc, adding an estimated $12.4M. The largest seller was Eventide Asset Management, cutting an estimated $659K.
- 55 institutional investors held Compass Therapeutics (CMPX) as of Q4 2022, up from 38 in Q3 2022.
- Funds reported $401M of Compass Therapeutics stock for Q4 2022, up 176% quarter-over-quarter.
- 19 funds opened new Compass Therapeutics positions in Q4 2022 and 1 closed out, a net change of +18 holders.
- The largest Compass Therapeutics buyer in Q4 2022 was Blackstone Inc, an estimated $12.4M added.
- The largest Compass Therapeutics seller in Q4 2022 was Eventide Asset Management, an estimated $659K sold.
Based on aggregated 13F filings for Q4 2022.